Venous Thromboembolism in Pediatrics

ABSTRACT

Venous thromboembolism (VTE) in pediatrics is quickly becoming a well-recognized cause of significant morbidity and mortality in children. Most children diagnosed with VTE have a serious underlying primary illness such as cancer, chronic total parenteral nutrition (TPN) dependency, or congenital heart disease. Infants and adolescents are most at risk of developing VTE, and the most significant risk factor is the presence of a central venous line (CVL). The incidence of VTE varies widely with study design and the diagnostic test used to detect thrombosis. Venography remains the gold standard diagnostic test, although ultrasound is increasingly used due to its noninvasive nature, despite concern regarding the sensitivity in upper system VTE. The treatment of uncomplicated VTE in children consists primarily of unfractionated heparin (UFH) initially, followed by oral anticoagulation or low molecular weight heparin (LMWH) for 3 months. LMWH offers many advantages over UFH due to the longer half-life, increased bioavailability, and ease of administration and monitoring in children. Acute complications of VTE in children are numerous and include pulmonary embolism (PE), chylothorax, and superior vena cava syndrome. Long-term morbidity includes recurrent VTE, postthrombotic syndrome, repeat general anesthetics for CVL placement, and eventual destruction of the upper venous system in children with repeat CVL-related VTE. Death from VTE is rare and is primarily due to PE.

KEYWORD

Thrombosis - central venous lines - pulmonary embolism

REFERENCES

• 1 Andrew M, Monagle P, Brooker L. Introduction. In: Thromboembolic Complications During Infancy and Childhood Hamilton, BC: Decker 2000 0: 1-3
• 2 Andrew M, David M, Adams M. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE.  Blood . 1994;  83 1251-1257
• 3 Monagle P, Adams M, Mahoney M. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry.  Pediatr Res . 2000;  47 763-766
• 4 David M, Andrew M. Venous thromboembolism complications in children: A Critical Review of the Literature.  J Pediatr . 1993;  123 337-346
• 5 Andrew M, Monagle P, Brooker L A. Epidemiology of venous thromboembolic events. In: Thromboembolic Complications During Infancy and Childhood Hamilton, BC: Decker 2000: 111-146
• 6 Andrew M, Marzinotto V, Pencharz P. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home.  J Pediatr . 1995;  126 358-363
• 7 Andrew M, Paes B, Milner R. Development of the human coagulation system in the healthy premature infant.  Blood . 1988;  72 1651-1657
• 8 Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen D M, Powers P. Development of the human coagulation system in the full-term infant.  Blood . 1987;  70 165-172
• 9 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood.  Blood . 1992;  80 1998-2005
• 10 Zipursky A, Jaber H. The hematology of bacterial infection in newborn infants.  Clin Hematol . 1978;  7 175-193
• 11 Katz J A, Moake J L, McPherson P D, Weinstein M J, Moise K J, Carpenter R J, Sala D J. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma.  Blood . 1989;  73 1851-1858
• 12 Stuart M J, Dusse J, Clark D A, Walenga R W. Differences in thromboxane production between neonatal and adult platelets in response to arachidonic acid and epinephrine.  Pediatr Res . 1984;  18 823-826
• 13 Andrew M, Mitchell L, Berry L. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.  J Clin Invest . 1992;  89 321-326
• 14 Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin.  Thromb Haemost . 1994;  72 836-842
• 15 Tait R C, Walker I D, Islam S I, Mitchell R, Conkie J A, McCall F, Davidson J F. Age related changes in protein C activity in healthy adult males.  Thromb Haemost . 1991;  65 326-327
• 16 Ganrot S, Schersten P. Serum α₂-macroglobulin concentration and its variation with age and sex.  Clin Chim Acta . 1967;  15 120
• 17 Levine J J, Udall J N, Evernden B A, Epstein M F, Bloch K J. Elevated levels of a-macroglobulin-protease complexes in infants.  Biol Neonate . 1987;  51 149
• 18 Schmidt B, Mitchell L, Ofosu F, Andrew M. Standard assays underestimate the concentration of heparin in neonatal plasma.  J Lab Clin Med . 1988;  112 641-643
• 19 Nowak-gottl U, Von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey.  Arch Dis Child Fetal Neonatal Ed . 1997;  76 F163-F167
• 20 Michelson A D, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children.  Chest . 1998;  114 748S-769S
• 21 De Stefano V, Leone G, De Carolis P M. Antithrombin III in full-term and pre-term newborn infants: three cases of neonatal diagnosis of AT III congenital defect.  Thromb Haemost . 1987;  57 329-331
• 22 Corby D G, Schulman I. The effects of antenatal drug administration on aggregation of platelets of newborn infants.  J Pediatr . 1971;  79 307-313
• 23 Manco-Johnson M J. Disorders of hemostasis in childhood: risk factors for venous thromboembolism.  Thromb Haemost . 1997;  78 710-714
• 24 Miletich J P, Prescott S M, White R, Majerus P W, Bovill E G. Inherited predisposition to thrombosis.  Cell . 1993;  72 477-480
• 25 Andrew M, Michelson A D, Bovill T, Leaker M, Massicotte P, Marzinotto V, Brooker L A. The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs.  J Pediatr Hematol Oncol . 1997;  19 7-22
• 26 Nowak-gottl U, Schneppenheim R, Vielhaber H. APC resistance in childhood thromboembolism: diagnosis and clinical aspects.  Semin Thromb Hemost . 1997;  23 253-258
• 27 Nowak-gottl U, Strater R, Dubbers A, Oleszuk-Raschke K, Vielhaber H. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene.  Blood Coagul Fibrinol . 1996;  7 684-688
• 28 Nowak-gottl U, Dubbers A, Kececioglu D, Koch H G, Kotthoff S, Runde J, Vielhaber H. Factor V Leiden, protein C, and lipoprotein(a) in catheter-related thrombosis in childhood: a prospective study.  J Pediatr . 1997;  131 608-612
• 29 Kohlhase B, Kececioglu D, Nowak-gottl U. Intracardiac thrombus associated with resistance to activated protein C.  Cardiol Young . 1998;  8 116-118
• 30 Nowak-gottl U, Vielhaber H, Schneppenheim R, Koch H G. Coagulation and fibrinolysis in children with APC-resistance: a population based study.  Fibrinolysis . 1996;  10 25-27
• 31 Nowak-gottl U, Auberger K, Gobel U. Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.  Eur J Pediatr . 1996;  155 921-927
• 32 Nowak-gottl U, Koch H G, Aschka I. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.  Br J Haematol . 1996;  92 992-998
• 33 Aschka I, Aumann V, Bergmann F. Prevalence of factor V Leiden in children with thrombo-embolism.  Eur J Pediatr . 1996;  155 1009-1014
• 34 Nowak-gottl U, Junker R, Hartmeier M, Koch H G, Munchow N, Assmann G, von Eckardstein A. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood.  Circulation . 1999;  100 743-748
• 35 Streif W, Andrew M. Venous thromboembolic events in pediatric patients.  Hematol/Oncol Clin North Am . 1998;  12 1283-1312
• 36 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.  Proc Natl Acad Sci USA . 1993;  90 1004-1008
• 37 Hirsh J. Approach to Patients with Inherited Thrombophilia.  Hamilton, BC: Decker; 1998
• 38 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden.  Lancet . 1995;  346 1133-1134
• 39 Lee D H, Henderson P, Blajchman M. Prevalence of factor V Leiden in a Canadian blood donor population.  Can Med Assoc J . 1996;  155 285-289
• 40 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
• 41 Makris M, Preston F E, Beauchamp N J. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia.  Thromb Haemost . 1997;  78 1426-1429
• 42 Price D T, Ridker P M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.  Ann Intern Med . 1997;  127 895-903
• 43 Cumming A M, Keeney S, Salden A, Bhavnani M, Shwe K H, Hay C R. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population.  Br J Haematol . 1997;  98 353-355
• 44 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene.  Br J Haematol . 1997;  98 907-909
• 45 Ferraresi P, Marchetti G, Legnani C. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease.  Arterioscler Thromb Vasc Biol . 1997;  17 2418-2422
• 46 Simioni P, Tormene D, Manfrin D, Gavasso S, Luni S, Stocco D, Girolami A. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant.  Br J Haematol . 1998;  103 1045-1050
• 47 Hessner M J, Luhm R A, Pearson S L, Endean D J, Friedman K D, Montgomery R R. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR.  Thromb Haemost. . 1999;  81 733-738
• 48 Rahimy M C, Krishnamoorthy R, Ahouignan G, Laffan M, Vulliamy T. The 20210A allele of prothrombin is not found among sickle cell disease patients from West Africa.  Thromb Haemost . 1998;  79 444-445
• 49 Isshiki I, Murata M, Watanabe R. Frequencies of prothrombin 20210 G→A mutation may be different among races-studies on Japanese populations with various forms of thrombotic disorders and healthy subjects.  Blood Coagul Fibrinol . 1998;  9 105-106
• 50 Miyata T, Kawasaki T, Fujimura H, Uchida K, Tsushima M, Kato H. The prothrombin gene G20210A mutation is not found among Japanese patients with deep vein thrombosis and healthy individuals.  Blood Coagul Fibrinol . 1998;  9 451-452
• 51 Zivelin A, Rosenberg N, Faier S. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene.  Blood . 1998;  92 1119-1124
• 52 Dilley A, Austin H, Hooper W C. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects.  J Lab Clin Med . 1998;  132 452-455
• 53 Hooper W C, Dilley A, Austin H. Absence of mutations at APC cleavage sites Arg306 in factor V and Arg336, Arg562 in factor VIII in African-Americans.  Thromb Haemost . 1998;  79 236
• 54 Dilley A, Austin H, Hooper W C. Relation of three genetic traits to venous thrombosis in an African-American population.  Am J Epidemiol . 1998;  147 30-35
• 55 Andrew M, Monagle P, Brooker L. Congenital prothrombotic disorders: presentation during infancy and childhood. In: Thromboembolic Complications During Infancy and Childhood Hamilton, BC: Decker 2000: 47-110
• 56 Bauer K. Rare hereditary coagulation factor abnormalities. In: Nathan DG, Oski FA, eds. Hematology of Infancy and Childhood Philadelphia: WB Saunders 1998: 1660-1675
• 57 Andrew M, Brooker L A. Hemostatic complications in renal disorders of the young.  Pediatr Nephrol . 1996;  10 88-99
• 58 Vielhaber H, Ehrenforth S, Koch H G, Scharrer I, van der N W, Nowak-gottl U. Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia.  Eur J Pediatr . 1998;  157 555-560
• 59 Hagstrom J N, Walter J, Bluebond-Langner R, Amatniek J C, Manno C S, High K A. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease.  J Pediatr . 1998;  133 777-781
• 60 Koster T, Rosendaal F R, Briet E. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study).  Blood . 1995;  85 2756-2761
• 61 Adcock D M, Brozna J, Marlar R A. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis.  Semin Thromb Hemost . 1990;  16 333-340
• 62 Adcock D M, Hicks M J. Dermatopathology of skin necrosis associated with purpura fulminans.  Semin Thromb Hemost . 1990;  16 283-292
• 63 Andrew M, Monagle P, Brooker L. Thromboembolic complications in specific organ sites and pediatric diseases. Thromboembolic Complications During Infancy and Childhood. Hamilton, BC: Decker; 2000: 231-276
• 64 Alarcon-Segovia D, Deleze M, Oria C. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus.  Medicine . 1989;  68 353-365
• 65 Dungan D D, Jay M S. Stroke in an early adolescent with systemic lupus erythematosus and coexistent antiphospholipid antibodies.  Pediatrics . 1992;  90 96-99
• 66 Pelkonen P, Simell O, Rasi V, Vaarala O. Venous thrombosis associated with lupus anticoagulant and anticardiolipin antibodies.  Acta Paediatr Scand . 1988;  77 767-772
• 67 Appan S, Boey M L, Lim K. Multiple thromboses in systemic lupus erythematosus.  Arch Dis Child . 1987;  62 739-741
• 68 Bernstein M L, Salusinsky-Sternbach M, Bellefleur M, Esseltine D W. Thrombotic and hemorrhagic complications in children with the lupus anticoagulant.  AJDC . 1984;  138 1132-1135
• 69 Olive D, Andre E, Brocard O, Labrude P, Alexandre P. Lupus érythémateux disséminé revéle par des thrombophlébites des membres inferieurs. [Systemic lupus erythematosus manifested by thrombophlebitis of the lower limbs].  Arch Fr Pediatr . 1979;  36 807-811
• 70 Ostuni P A, Lazzarin P, Pengo V, Ruffatti A, Schiavon F, Gambari P. Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome.  Ann Rheum Dis . 1990;  49 184-187
• 71 Kwong T, Leonidas J C, Ilowite N T. Asymptomatic superior van cava thrombosis and pulmonary embolism in an adolescent with SLE and antiphospholipid antibodies.  Clin Experim Rheumatol . 1994;  12 215-217
• 72 Rider L, Clarke W, Rutledge J. Pulmonary hypertension in a seventeen-year-old boy.  J Pediatr . 1992;  120 149-159
• 73 Berube C, Mitchell L, David M. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus in children: A cross-sectional study.  Pediatr Res . 1998;  44 351-356
• 74 Andrew M. Acquired Disorders in Children. In: Nathan DG, Oski FA, eds. Hematology: Of Infancy and Childhood, Vol 2 Philadelphia: WB Saunders 1998: 1677-1717
• 75 Andrew M. Developmental hemostasis: relevance to newborns and infants. In: Nathan DG, Orkin SH, eds. Hematology: Of Infancy and Childhood, vol 1 Philadelphia: WB Saunders 1998: 114-157
• 76 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry.  Pediatrics . 1995;  96 939-943
• 77 Massicotte M P, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications.  J Pediatr . 1998;  133 770-776
• 78 Mollitt D L, Golladay E S. Complications of TPN catheter-induced vena caval thrombosis in children less than one year of age.  J Pediatr Surg . 1983;  18 462-467
• 79 Marie I, Levesque H, Cailleux N, Primard E, Peillon C, Watelet J, Courtois H. [Deep venous thrombosis of the upper limbs.  Apropos of 49 cases]. Rev Med Interne . 1998;  19 399-408
• 80 Mulvihill S J, Fonkalsrud E W. Complications of superior versus inferior vena cava occlusion in infants receiving central total parenteral nutrition.  J Pediatr Surg . 1984;  19 752-757
• 81 Rockoff M A, Gang D L, Vacanti J P. Fatal pulmonary embolism following removal of a central venous catheter.  J Pediatr Surg . 1984;  19 307-309
• 82 Derish M T, Smith D W, Frankel L R. Venous catheter thrombus formation and pulmonary embolism in children.  Pediatr Pulmonol . 1995;  20 349-354
• 83 Ament J, Newth C J. Deep venous lines and thromboembolism [editorial; comment].  Pediatr Pulmonol . 1995;  20 347-348
• 84 Hoyer P F, Gonda S, Barthels M, Krohn H P, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence.  Acta Paediatr Scand . 1986;  75 804-810
• 85 Pollard A J, Sreeram N, Wright J G, Beath S V, Booth I W, Kelly D A. ECG and echocardiographic diagnosis of pulmonary thromboembolism associated with central venous lines.  Arch Dis Child . 1995;  73 147-150
• 86 Dollery C M, Sullivan I D, Bauraind O, Bull C, Milla P J. Thrombosis and embolism in long-term central venous access for parenteral nutrition.  Lancet . 1994;  344 1043-1045
• 87 Uderzo C, Faccini P, Rovelli A. Pulmonary thromboembolism in childhood leukemia: 8-years' experience in a pediatric hematology center.  J Clin Oncol . 1995;  13 2805-2812
• 88 Kramer S S, Taylor G A, Garfinkel D J, Simmons M A. Lethal chylothoraces due to superior vena caval thrombosis in infants.  Am J Roentgenol . 1981;  137 559-563
• 89 Dhande V, Kattwinkel J, Alford B. Recurrent bilateral pleural effusions secondary to superior vena cava obstruction as a complication of central venous catheterization.  Pediatrics . 1983;  72 109-113
• 90 Kurekci E, Kaye R, Koehler M. Chylothorax and chylopericardium: a complication of a central venous catheter.  J Pediatr . 1998;  132 1064-1066
• 91 Graham Jr L, Gumbiner C H. Right atrial thrombus and superior vena cava syndrome in a child.  Pediatrics . 1984;  73 225-229
• 92 Bertrand M, Presant C A, Klein L, Scott E. Iatrogenic superior vena cava syndrome. A new entity.  Cancer . 1984;  54 376-378
• 93 White R, McGahan J, Daschback M, Hartling R. Diagnosis of deep-vein thrombosis using duplex ultrasound.  Ann Intern Med . 1989;  111 297-304
• 94 Mitchell L, Chait P, Ginsberg J, Hanna K, Andrew M. Comparison of venography with ultrasound for detection of venous thrombosis in the upper body in children: results of the PARKAA study.  Blood (Suppl 1, Pt 1 of 2):55a.
• 95 Bonnet F, Loriferne J F, Texier J P, Texier M, Salvat A, Vasile N. Evaluation of Doppler examination for diagnosis of catheter-related deep vein thrombosis.  Intensive Care Med . 1989;  15 238-240
• 96 Andrew M, Michelson A D, Bovill E, Leaker M, Massicotte M P. Guidelines for antithrombotic therapy in pediatric patients.  J Pediatr . 1998;  132 575-588
• 97 Streif W, Andrew M, Marzinotto V, Massicotte P, Chan A K, Julian J A, Mitchell L. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients.  Blood . 1999;  94 3007-3014
• 98 Olson S T, Shore J D. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement.  J Biol Chem . 1981;  256 11065-11072
• 99 Hirsh J. Heparin.  N Engl J Med . 1991;  324 1565-1574
• 100 Andrew M, Marzinotto V, Blanchette V. Heparin therapy in pediatric patients: A prospective cohort study.  Pediatr Res . 1994;  35 78-83
• 101 Cruickshank M K, Levine M N, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy.  Arch Intern Med . 1991;  151 333-337
• 102 Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.  Lancet . 1986;  2 1293-1296
• 103 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.  N Engl J Med . 1990;  322 1260-1264
• 104 Kelton J, Smith J, Warkentin T, Hayward C, Denomme G, Horsewood P. Immunoglobulin G from patients with heparin induced thrombocytopenia binds to a complex of heparin and platelet factor 4.  Blood . 1994;  83 3232-3239
• 105 Kelton J. Heparin-induced thrombocytopenia.  Haemostasis . 1986;  16 173-186
• 106 Kelton J, Powers P. Heparin-Associated Thrombocytopenia: An Immune Disorder.  New York: Elsevier 1981: 365-375
• 107 Kelton J, Sheridan D, Santos A. Heparin-associated thrombocytopenia: laboratory studies.  Blood . 1988;  72 925-930
• 108 Warkentin T, Kelton J. Heparin-induced thrombocytopenia.  Prog Haemost Thromb . 1991;  10 1-34
• 109 Andrew M, Brooker L A, Ginsberg J S, Kelton J G. Clinical problems in anticoagulation therapy. In: Schecter AP et al (eds) Hematology 1997; The American Society of Hematology Education Program Book. San Francisco: 1997: 8-28
• 110 Warkentin T, Kelton J. Heparin-induced thrombocytopenia.  Annu Rev Med . 1989;  40 31-44
• 111 King D, Kelton J. Heparin-associated thrombocytopenia.  Ann Intern Med . 1984;  100 535-540
• 112 Spadone D, Clark F, James E, Laster J, Hoch J, Silver D. Heparin-induced thrombocytopenia in the newborn.  J Vasc Surg . 1996;  15 306-311
• 113 Magnani H. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172).  Thromb Haemost . 1993;  70 554-561
• 114 Murphy M. Heparin therapy and bone fractures.  Lancet . 1992;  340 1098-1099
• 115 Schuster J. Pathology of osteopathy following heparin therapy.  Deut Mediz Wochen . 1969;  94 2334-2338
• 116 Ofosu F A. In vitro and ex-vivo activities of CY216: comparison with other low molecular weight heparins.  Haemostasis . 1990;  180 (180)
• 117 Weitz J I. Low molecular weight heparins.  N Engl J Med . 1997;  337 688-698
• 118 Kuijer P MM, Prins M H, Buller H R. Low molecular weight heparins: treatment of venous thromboembolism. In: Sashara AA, Loscalzo J, eds. Advances in Therapeutic Agents in Thrombosis and Thrombolysis New York: Marcel Dekker 1997: 129-147
• 119 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparision of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.  Thromb Haemostas . 1994;  71 7-11
• 120 Aballi A J, de Lamerens S. Coagulation changes in the neonatal period and in early infancy.  Pediatr Clin North Am . 1962;  9 785-817
• 121 Shearer M J, Barkhan P, Rahim S, Stimmler L. Plasma vitamin K₁ in mothers and their newborn babies.  Lancet . 1982;  2 460-463
• 122 Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long term warfarin therapy.  Thromb Haemostas . 1999;  Suppl 1333a
• 123 Corrigan Jr J J, Sleeth J J, Jeter M, Lox C D. Newborn's fibrinolytic mechanism: components and plasmin generation.  Am J Hematol . 1989;  32 273-278
• 124 Leaker M, Brooker L A, Mitchell L, Weitz J, Superina R, Andrew M E. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.  Transplantation . 1995;  60 144-147
• 125 Hirsh J, Salzman E W, Marder V J. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis Basic Principles and Clinical Practice Philadelphia: JP Lippincott 1994: 1346-1366
• 126 Leaker M, Massicotte M P, Brooker L A, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature.  Thromb Haemost . 1996;  76 132-134
• 127 Andrew M, Monagle P, Brooker L. Thrombolytic therapy. In: Thromboembolic Complications During Infancy and Childhood Hamilton, BC: Decker 2000: 357-384
• 128 Nawroth P, Handley D, Esmon C, Stern D. Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.  Proc Natl Acad Sci USA . 1986;  83 4533
• 129 Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery.  J Cardiothorac Anesth . 1989;  3 181-188
• 130 Andrew M, Monagle P, Brooker L. Pulmonary embolism in childhood. In: Thromboembolic Coomplications During Infancy and Childhood Hamilton, BC: Decker 2000: 147-164
• 131 Anton N, Massicotte M P, Cox P. The incidence of symptomatic central venous line thrombosis in infants with congenital heart disease. World Congress of Pediatric Intensive Care Montreal, 2000
• 132 Hull R D, Raskob G E, Hirsh J. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.  N Engl J Med . 1986;  315 1109-1114
• 133 Swinton Jr W N, Edgett Jr W J, Hall R J. Primary subclavian-axillary vein thrombosis.  Circulation . 1968;  38 737-745
• 134 Tilney M L, Griffiths H J, Edwards E A. Natural history of major venous thrombosis of the upper extremity.  Arch Surg . 1970;  101 792-796
• 135 Painter T D, Karpf M. Deep venous thrombosis of the upper extremity five years experience at a university hospital.  Angiology . 1984;  35 743-749
• 136 Lindblad B, Bergqvist D. Aggressive or conservative treatment in subclavian vein thrombosis. In: Eklof B, Gjores JE, Thulesdius O, Bergqvist D, eds. Controversies in the Management of Venous Disorders London: Butterworths 1989: 141-148
• 137 Randolph A G, Cook D J, Gonzales C A. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials.  Chest . 1998;  113 165-171
• 138 Andrew M, PROTEKT Investigators. A randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: the PROTEKT trial. American Society of Hematology Meeting, San Francisco: December 2000
• 139 Krafte-Jacobs B, Sivit C J, Mejia R, Pollack M M. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding.  J Pediatr . 1995;  126 50-54
• 140 Pierce C M, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children [in process citation].  Intensive Care Med . 2000;  26 967-972
• 141 Massicotte M P, Adams M, Leaker M, Andrew M. A nomogram to establish therapeutic levels of the low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolism (VTE).  Thromb Haemostas . 1997;  Suppl 282